Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Standard
Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. / Kröger, Nicolaus.
In: HEMATOL-AM SOC HEMAT, 2008, p. 60-67.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
AU - Kröger, Nicolaus
PY - 2008
Y1 - 2008
N2 - Allogeneic stem cell transplantation can cure patients with myelodysplastic syndromes. However, more than 50% of the patients who underwent allogeneic stem cell transplantation have failed to benefit from this treatment approach either due to treatment-related mortality or to relapse. The introduction of toxicity or dose-reduced conditioning has significantly reduced the treatment-related mortality but did not affect the risk of relapse. New effective drugs, such as hypomethylating agents, histone-deacetylase inhibitors or lenalidomide, can be used alone or in combination to improve the pretransplant remission status before allogeneic stem cell transplantation or after transplantation to prevent relapse as maintenance or consolidation therapy. This review will focus on these new possibilities and give some perspectives as to how the results of allogeneic stem cell transplantation can be further improved.
AB - Allogeneic stem cell transplantation can cure patients with myelodysplastic syndromes. However, more than 50% of the patients who underwent allogeneic stem cell transplantation have failed to benefit from this treatment approach either due to treatment-related mortality or to relapse. The introduction of toxicity or dose-reduced conditioning has significantly reduced the treatment-related mortality but did not affect the risk of relapse. New effective drugs, such as hypomethylating agents, histone-deacetylase inhibitors or lenalidomide, can be used alone or in combination to improve the pretransplant remission status before allogeneic stem cell transplantation or after transplantation to prevent relapse as maintenance or consolidation therapy. This review will focus on these new possibilities and give some perspectives as to how the results of allogeneic stem cell transplantation can be further improved.
M3 - SCORING: Zeitschriftenaufsatz
SP - 60
EP - 67
JO - HEMATOL-AM SOC HEMAT
JF - HEMATOL-AM SOC HEMAT
SN - 1520-4391
ER -
